ARS Pharmaceuticals Inc (NASDAQ: SPRY) started the day on Wednesday, with a price increase of 5.14% at $10.44, before settling in for the price of $9.93 at the close. Taking a more long-term approach, SPRY posted a 52-week range of $6.66-$18.90.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -2241.67%. This publicly-traded company’s shares outstanding now amounts to $98.84 million, simultaneously with a float of $59.72 million. The organization now has a market capitalization sitting at $1.03 billion. At the time of writing, stock’s 50-day Moving Average stood at $9.38, while the 200-day Moving Average is $12.81.
ARS Pharmaceuticals Inc (SPRY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. ARS Pharmaceuticals Inc’s current insider ownership accounts for 39.58%, in contrast to 63.79% institutional ownership. According to the most recent insider trade that took place on Nov 13 ’25, this organization’s Chief Operating Officer sold 21,828 shares at the rate of 8.71, making the entire transaction reach 190,050 in total value, affecting insider ownership by 10,789. Preceding that transaction, on Nov 12 ’25, Company’s Chief Business Officer sold 166,380 for 8.87, making the whole transaction’s value amount to 1,476,147. This particular insider is now the holder of 0 in total.
ARS Pharmaceuticals Inc (SPRY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year. ARS Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -2241.67% and is forecasted to reach -1.29 in the upcoming year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Let’s observe the current performance indicators for ARS Pharmaceuticals Inc (SPRY). It’s Quick Ratio in the last reported quarter now stands at 6.51. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.23.
In the same vein, SPRY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.81, a figure that is expected to reach -0.42 in the next quarter, and analysts are predicting that it will be -1.29 at the market close of one year from today.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
If we take a close look at the recent performances of ARS Pharmaceuticals Inc (NASDAQ: SPRY), its last 5-days Average volume was 1.64 million that shows plunge from its year to date volume of 1.87 million. During the previous 9 days, stock’s Stochastic %D was recorded 85.28% While, its Average True Range was 71.02.
Raw Stochastic average of ARS Pharmaceuticals Inc (SPRY) in the period of the previous 100 days is set at 31.58%, which indicates a major fall in contrast to 98.44% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.64 that was lower than 0.68 volatility it exhibited in the past 100-days period.
